-
1صورة
المؤلفون: Martha Valle-Solis, Jeni Bolaños, Esther Orozco, Miriam Huerta, Guillermina García-Rivera, Andrés Salas-Casas, Bibiana Chávez-Munguía, Mario A. Rodríguez
مصطلحات موضوعية: Clinical Microbiology, Medical Bacteriology, Medical Infection Agents (incl. Prions), Medical Virology, Entamoeba histolytica, calcium/cation exchanger, protein overexpression, programmed cell death, virulence
الإتاحة: https://doi.org/10.3389/fcimb.2018.00342.s001Test
https://figshare.com/articles/figure/Image_1_A_Calcium_Cation_Exchanger_Participates_in_the_Programmed_Cell_Death_and_in_vitro_Virulence_of_Entamoeba_histolytica_TIF/7151258Test -
2تقرير
المساهمون: Ding-Wei Ye, Clinical Professor
المصدر: A Prospective, Open, Single-center Clinical Study of Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06187506Test
-
3تقرير
المصدر: DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06055153Test
-
4تقرير
المصدر: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05904730Test
-
5تقرير
المصدر: PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05868226Test
-
6تقرير
المصدر: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05511844Test
-
7تقرير
المؤلفون: AstraZeneca
المصدر: BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal Junction
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05480384Test
-
8تقرير
المصدر: A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05363605Test
Other URLs: http://fusionpharma.comTest
-
9تقرير
المساهمون: Morten Mau-Sørensen, MD PhD
المصدر: HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05170256Test
-
10تقرير
المؤلفون: Center for Cell and Gene Therapy, Baylor College of Medicine, The Faris Foundation USA, Stand Up To Cancer, Triumph Over Kid Cancer Foundation, St. Baldrick's Foundation, National Cancer Institute (NCI)
المساهمون: Meenakshi Hegde, M.D., Associate Professor
المصدر: Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04995003Test
Other URLs: https://rarediseases.info.nih.govTest/